Abomics Ltd is a 2013 founded Finnish company that specializes in translating genomics research into clinical practice and provides new approaches to personalized medicine. The fundamental idea behind Abomics is to translate evidence-based research knowledge into clear recommendations that both the treating physician and the patient will understand and benefit from. Abomics provides comprehensive pharmacogenetic services, such as Abomics GeneRx pharmacogenetic database, Abomics PGx Interpretation Service and Abomics GeneAccount cloud service to health care professionals, organizations and consumers on a global scale.
Learn more about Abomics and their pharmacogenetic services by listening the interview with CEO Jari Forsström:
Further information: http://www.abomics.fi/en/